ArticleIUCrJ2026
Linear-scaling aspherical crystallographic refinement of proteins: a case study for crambin and rubredoxin.
Article in IUCrJ, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Towards routine accurate electron-density studies of biological macromolecules.Acta crystallographica. Section D, Structural biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Hirshfeld atom refinement (HAR) provides a more realistic interpretation of crystallographic data than the standard independent atom model (IAM) by using aspherical atomic form factors derived from quantum mechanical (QM) calculations. With this aspherical description, it is possible to obtain improved atomic positions, atomic displacement parameters and correct bond lengths even for hydrogen atoms. Unfortunately, HAR is computationally very demanding for larger molecules. Recently, we suggested how this can be solved by calculating aspherical atomic form factors for small overlapping fragments of the system, the fragHAR approach. Here, we have created a new implementation of fragHAR in Olex2 within the NoSpherA2 interface. We have also solved previous issues with hydrogen bonds by automatically extending the fragments with all hydrogen-bond acceptors. This implementation was successfully tested on three oligopeptides, demonstrating that fragHAR yields indistinguishable results in terms of atomic charge, residual density or R values compared with full HAR. Subsequently, fragHAR was applied to the proteins crambin and rubredoxin, with 843 and 1014 atoms, respectively, showing improved results in terms of e
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.